FOR: CARDIOCOMM SOLUTIONS, INC.
TSX VENTURE SYMBOL: EKG
December 18, 2017
TORONTO, ONTARIO – Global medical electrocardiogram ("ECG") software and device manufacturer CardioComm Solutions, Inc. (TSX VENTURE:EKG) ("CardioComm Solutions" or the "Company"), today confirmed that it has officially released GEMS™ Home Flex for HeartCheck™ ECG devices that work on either a Mac or Windows operating system.
Availability of the newly released GEMS™ Home Flex will support expanded use of both the HeartCheck™ ECG PEN and the HeartCheck™ ECG Handheld monitor by consumers, patients and healthcare professionals. The HeartCheck™ ECG PEN is available to consumers online directly from CardioComm and also at over 800 Canadian pharmacy locations, including Shoppers Drug Mart. The HeartCheck™ ECG Handheld monitor is sold by CardioComm to patients and physicians as a prescription device. The prescription device is favored by the medical community as it offers the added benefit of being able to acquire an ECG recording through the use of traditional ECG cables and electrodes as well as through the handheld method. The GEMS™ Home Flex release follows the launch of the Canadian TEMPO ECG monitor loan program. Under the TEMPO agreement, CardioComm will provide select heart failure clinics currently equipped with MAC computers with the HeartCheck™ ECG Handheld monitors.
GEMS™ Home FLEX will support all HeartCheck™ devices already sold. Windows-based customers that wish to switch their version of GEMS™ Home to the newly redesigned GEMS™ Home Flex interface may contact CardioComm directly for more information.
CardioComm Solutions was the first company to receive Canadian and US regulatory approvals for the Over-The-Counter (OTC) sale of a consumer device allowing any person to take their own ECG anywhere. Since the commercial release of the HeartCheck™ ECG PEN, CardioComm Solutions has continued to work to broaden consumer access to a larger range of easy-to-use consumer and medical-wellness products. Through commitments made to medical and consumer health monitoring device manufacturers, CardioComm will provide access to their well-developed hospital ECG connectivity and GEMS™ based technologies as a device-agnostic medical software “back office” solution.
These commitments will provide CardioComm's developing sports, wellness and telemedicine partners with trusted and proven device communication, connectivity and data management solutions. These solutions will help to transform their industries, set new industry trends and standards of excellence and provide continued innovations through the introduction of disruptive and easy-to-use consumer health monitoring technologies.
CardioComm Solutions will be providing further updates regarding the release of new medical and consumer ECG recording technologies, including the planned release of GEMS™ Mobile. GEMS™ Mobile will be an Android and iOS compatible Smartphone application that will allow multiple wireless HeartCheck™ compliant ECG monitoring devices to be connected to a Smartphone. In addition, the application will provide physicians' offices access to the SMART Monitoring ECG reading service and provide healthcare professionals with near real-time access to medical-grade ECG reports.
CardioComm Solutions has earned the ISO 13485 certification, is HPB approved, HIPAA compliant and holds clearances for the sale of the HeartCheck™ technologies from the European Union (CE Mark), the USA (FDA), China (CFDA) and Canada (Health Canada). To learn more about the CardioComm Solutions' products, please see the Company's websites www.theheartcheck.com and www.cardiocommsolutions.com or contact the Company at firstname.lastname@example.org.
CardioComm Solutions' patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. CardioComm Solutions is headquartered in Toronto, Ontario, Canada.
INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
This release may contain certain forward-looking statements and forward looking information with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. Such statements and information reflect management’s current beliefs and are based on information currently available to management. By their nature, forward-looking statements and forward-looking information involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forward-looking information.
In evaluating these statements, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not assume any obligation to update the forward-looking statements and forward-looking information contained in this release other than as required by applicable laws, including without limitation, Section 5.8(2) of National Instrument 51-102 (Continuous Disclosure Obligations).
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.